Cesca Therapeutics I (KOOL) 4.00 $KOOL
Cesca Therapeutics Granted Two Patents for Rapid Infusion of Autologous Bone Marrow Derived Stem Cells
GlobeNewswire - Mon Sep 19, 5:00AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the United States Patent & Trademark Office (USPTO) has granted the Company the first two of a family of patent applications related to Cesca's proprietary methods for the treatment of ischemic cardiovascular disorders, such as critical limb ischemia (CLI) and acute myocardial infarction (AMI). The patents (numbered 9,393,269 and 9,402,867) protect key components of Cesca's SurgWerks(TM) technology platform, designed for the delivery of autologous regenerative stem cell therapies in a point-of-care environment. The Company previously announced that the SurgWerks(TM) platform had been approved by the FDA for use in Cesca's phase III, pivotal trial for the treatment of late stage, poor option and no option CLI patients.
KOOL: 4.00 (-0.03)
Cesca Therapeutics to Report Fiscal Fourth Quarter and Full Year 2016 Financial Results and Provide Business Update
GlobeNewswire - Fri Sep 16, 5:00AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that it will report financial results for the fiscal fourth quarter and full year ended June 30, 2016 and provide a business update to investors on Tuesday, September 20, 2016.
KOOL: 4.00 (-0.03)
Cesca Therapeutics to Present at the 18th Annual Rodman & Renshaw(R) Global Investment Conference
GlobeNewswire - Thu Sep 08, 12:00PM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Michael Bruch, Cesca's Chief Financial Officer, and Dalip Sethi, Ph.D., Director of Clinical Research will present at the Rodman & Renshaw(R) 18 Annual Global Investment Conference, being held at The Lotte New York Palace Hotel in New York on September 11-13, 2016
KOOL: 4.00 (-0.03)
Arcadia Biosciences Names New Chief Financial Officer
BusinessWire - Thu Sep 08, 7:00AM CDT
Arcadia Biosciences, Inc. (Nasdaq: RKDA), an agricultural technology company that creates value for farmers while benefitting the environment and enhancing human health, announced today that Matthew T. Plavan will join the company's executive team as chief financial officer on September 12.
KOOL: 4.00 (-0.03), RKDA: 2.04 (+0.03)
Cesca Therapeutics Announces Conversion of $12.5 Million in Senior Secured Debt to Equity
GlobeNewswire - Wed Aug 24, 8:00PM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company has converted a senior secured three year convertible debenture of $12.5 million of principal and $8.25 million of interest to 6,102,941 shares of its common stock. The conversion was effected in accordance with the previously announced purchase agreement entered into between Cesca Therapeutics and Boyalife USA, dated February 2, 2016. It releases Cesca from all security interest and liens previously placed against the Company's assets and eliminates Boyalife's entitlement to certain participation rights in, or consent rights over, potential future equity and debt financings.
KOOL: 4.00 (-0.03)
Cesca Therapeutics Announces Pricing of $2.5 Million Registered Direct Offering
GlobeNewswire - Thu Aug 04, 8:08AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that it has entered into definitive subscription agreements with institutional investors to purchase 600,000 shares of common stock at a purchase price per share of $4.10 for gross proceeds of approximately $2.5 million in a registered direct offering. No warrants were issued to investors in the offering. The closing of the transaction is expected to occur on August 9, 2016, subject to the satisfaction of customary closing conditions.
KOOL: 4.00 (-0.03)
Cesca Therapeutics Announces Promising Results From 40-Month Follow-Up of Patients Enrolled in Critical Limb Ischemia Feasibility Study
GlobeNewswire - Wed Aug 03, 5:00AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced 40-month follow-up results for a number of patients that participated in the Company's earlier feasibility study using Cesca's proprietary SurgWerks(TM) system for the treatment of late stage, "no option" critical limb ischemia (CLI).
KOOL: 4.00 (-0.03)
Cesca Therapeutics Announces Publication of Results on Use of Its Technology for Treatment of Non-Union Fracture
GlobeNewswire - Tue Aug 02, 5:01AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that data for its proprietary technology was published in the Herald Scholarly Open Access (HSOA) Journal of Stem Cells Research, Development and Therapy, which is available online at http://ow.ly/ZFzM300Yt1m.
KOOL: 4.00 (-0.03)
Cesca Therapeutics Provides Update on FDA Review of Investigational Device Exemption Supplement for SurgWerks(TM) CLI Pivotal Trial
GlobeNewswire - Mon Aug 01, 5:00AM CDT
FDA Approves Commencement of Phase III Pivotal Trial as Amended
KOOL: 4.00 (-0.03)
Cesca Therapeutics Appoints Mark Bagnall to Its Board of Directors
GlobeNewswire - Mon Jun 20, 5:05AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Mr. Mark Bagnall has been appointed to the Company's Board of Directors, effective July 1, 2016.
KOOL: 4.00 (-0.03)
Cesca Therapeutics to Exhibit at 14th International Cord Blood Symposium
GlobeNewswire - Wed Jun 08, 5:05AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company will be exhibiting at the 14 International Cord Blood Symposium (ICBS), being held June 9-11 at the Hyatt Regency Hotel in San Francisco, California. As a leader in concentrating and cryopreserving stem cells from cord blood, Cesca is proud to sponsor the event.
KOOL: 4.00 (-0.03)
Cesca Therapeutics to Present at the LD Micro Invitational Conference
GlobeNewswire - Mon Jun 06, 5:05AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Mr. Michael Bruch, the Company's Chief Financial Officer and Dalip Sethi, Ph.D., Clinical Research Director, will discuss recent corporate developments and initiatives at the LD Micro Invitational, being held June 7 - 9, 2016 at the Luxe Sunset Hotel in Los Angeles.
KOOL: 4.00 (-0.03)
Cesca Therapeutics Submits Investigational Device Exemption Supplement for SurgWerks(TM) CLI Pivotal Trial
GlobeNewswire - Wed Jun 01, 10:15AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company has submitted an Investigational Device Exemption (IDE) Supplement to the U.S. Food and Drug Administration (FDA) for its previously approved pivotal trial for the treatment of patients with critical limb ischemia (CLI), using the Company's SurgWerks system. The Company expects the FDA to submit its response to the IDE supplement within 30 days of submission.
KOOL: 4.00 (-0.03)
Cesca Therapeutics to Exhibit at the 2016 International Society for Cellular Therapy Annual Meeting
GlobeNewswire - Tue May 24, 5:00AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company will be exhibiting at the 2016 International Society for Cellular Therapy (ISCT) Annual Meeting in Booth B06 on May 25-28, 2016 at the Suntec Convention and Exhibition Center in Suntec City, Singapore.
KOOL: 4.00 (-0.03)
Cesca Therapeutics to Review Recent Corporate Milestones at the Marcum MicroCap Conference
GlobeNewswire - Fri May 20, 5:00AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company's management team including, Mr. Robin Stracey, Chief Executive Officer, Mr. Michael Bruch, Chief Financial Officer and Dalip Sethi, Ph.D., Clinical Research Director, will discuss recent corporate developments and initiatives at the Marcum MicroCap Conference, which is being held June 1 - 2, 2016 at the Grand Hyatt Hotel in New York City.
KOOL: 4.00 (-0.03)
4 Stocks to Watch on Thursday May 19
ACCESSWIRE - Thu May 19, 1:02PM CDT
CORAL GABLES, FL / ACCESSWIRE / May 19, 2016 / TechStockInsider.com issues the following report: Today is an historic day in the market. It marks the anniversary of The Dow Jones Industrial Average having a record close of 18,312.39. But despite this very positive high in market history, investors have been hit with a rocky trading session on Thursday morning. This has left many, searching for stocks that have found an uptrend and we have been able to identify four stocks that investors are buying up on May 19.
KOOL: 4.00 (-0.03), PRGN: 0.73 (-0.03), GLBS: 0.64 (-0.01)
Cesca Therapeutics Announces Publication of a Case Report on Use of Its Technology for Treatment of Acute Myocardial Infarction
GlobeNewswire - Thu May 19, 5:00AM CDT
Data highlights promising results obtained from the AMIRST pilot study.
KOOL: 4.00 (-0.03)
Cesca Therapeutics Reports Third Quarter Fiscal 2016 Results and Provides Business Update
GlobeNewswire - Thu May 12, 3:37PM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today reported financial results for the third quarter of fiscal 2016 and provided an update to investors that included the status of clinical initiatives, with a particular emphasis on the Company's critical limb ischemia (CLI) program. The Company expects to submit an Investigational Device Exemption (IDE) supplement to the FDA at the end of the month detailing a range of changes to the pivotal CLI trial design and amendments to its CLI study protocol. The supplement will touch on, among other things, study end-points, the statistical analysis plan, the required patient enrollment totals for both the treatment arm and the control arm, patient inclusion/exclusion criteria and protocol changes designed to enhance patient enrollment.
KOOL: 4.00 (-0.03)
Cesca Reports Data From Six CLI Compassionate Use Patients Treated With SurgWerks(TM) Procedures at Fortis Escorts Heart Institute in New Delhi
GlobeNewswire - Wed May 11, 5:00AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced the results of six late-stage critical limb ischemia (CLI) patients treated with its SurgWerks(TM)-CLI system on a compassionate use basis. In a six-month follow-up of the patients, they reported favorable outcomes in lifestyle and pain reduction. The procedures were conducted by Dr. Suhail Bukhari of the Fortis Escorts Heart Institute and Research Center in New Delhi, India.
KOOL: 4.00 (-0.03)
Cesca Therapeutics to Report Third Quarter Fiscal 2016 Results on May 12, 2016
GlobeNewswire - Mon May 09, 5:00PM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that it will report financial results for the fiscal third quarter ended March 31, 2016 and provide a status update to investors on Thursday, May 12, 2016.
KOOL: 4.00 (-0.03)
Cesca Therapeutics Granted Two Patents for Rapid Infusion of Autologous Bone Marrow Derived Stem Cells
GlobeNewswire - Mon Sep 19, 5:00AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the United States Patent & Trademark Office (USPTO) has granted the Company the first two of a family of patent applications related to Cesca's proprietary methods for the treatment of ischemic cardiovascular disorders, such as critical limb ischemia (CLI) and acute myocardial infarction (AMI). The patents (numbered 9,393,269 and 9,402,867) protect key components of Cesca's SurgWerks(TM) technology platform, designed for the delivery of autologous regenerative stem cell therapies in a point-of-care environment. The Company previously announced that the SurgWerks(TM) platform had been approved by the FDA for use in Cesca's phase III, pivotal trial for the treatment of late stage, poor option and no option CLI patients.
KOOL: 4.00 (-0.03)
Cesca Therapeutics to Report Fiscal Fourth Quarter and Full Year 2016 Financial Results and Provide Business Update
GlobeNewswire - Fri Sep 16, 5:00AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that it will report financial results for the fiscal fourth quarter and full year ended June 30, 2016 and provide a business update to investors on Tuesday, September 20, 2016.
KOOL: 4.00 (-0.03)
Cesca Therapeutics to Present at the 18th Annual Rodman & Renshaw(R) Global Investment Conference
GlobeNewswire - Thu Sep 08, 12:00PM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Michael Bruch, Cesca's Chief Financial Officer, and Dalip Sethi, Ph.D., Director of Clinical Research will present at the Rodman & Renshaw(R) 18 Annual Global Investment Conference, being held at The Lotte New York Palace Hotel in New York on September 11-13, 2016
KOOL: 4.00 (-0.03)
Arcadia Biosciences Names New Chief Financial Officer
BusinessWire - Thu Sep 08, 7:00AM CDT
Arcadia Biosciences, Inc. (Nasdaq: RKDA), an agricultural technology company that creates value for farmers while benefitting the environment and enhancing human health, announced today that Matthew T. Plavan will join the company's executive team as chief financial officer on September 12.
KOOL: 4.00 (-0.03), RKDA: 2.04 (+0.03)
Cesca Therapeutics Announces Conversion of $12.5 Million in Senior Secured Debt to Equity
GlobeNewswire - Wed Aug 24, 8:00PM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company has converted a senior secured three year convertible debenture of $12.5 million of principal and $8.25 million of interest to 6,102,941 shares of its common stock. The conversion was effected in accordance with the previously announced purchase agreement entered into between Cesca Therapeutics and Boyalife USA, dated February 2, 2016. It releases Cesca from all security interest and liens previously placed against the Company's assets and eliminates Boyalife's entitlement to certain participation rights in, or consent rights over, potential future equity and debt financings.
KOOL: 4.00 (-0.03)
Cesca Therapeutics Announces Pricing of $2.5 Million Registered Direct Offering
GlobeNewswire - Thu Aug 04, 8:08AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that it has entered into definitive subscription agreements with institutional investors to purchase 600,000 shares of common stock at a purchase price per share of $4.10 for gross proceeds of approximately $2.5 million in a registered direct offering. No warrants were issued to investors in the offering. The closing of the transaction is expected to occur on August 9, 2016, subject to the satisfaction of customary closing conditions.
KOOL: 4.00 (-0.03)
Cesca Therapeutics Announces Promising Results From 40-Month Follow-Up of Patients Enrolled in Critical Limb Ischemia Feasibility Study
GlobeNewswire - Wed Aug 03, 5:00AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced 40-month follow-up results for a number of patients that participated in the Company's earlier feasibility study using Cesca's proprietary SurgWerks(TM) system for the treatment of late stage, "no option" critical limb ischemia (CLI).
KOOL: 4.00 (-0.03)
Cesca Therapeutics Announces Publication of Results on Use of Its Technology for Treatment of Non-Union Fracture
GlobeNewswire - Tue Aug 02, 5:01AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that data for its proprietary technology was published in the Herald Scholarly Open Access (HSOA) Journal of Stem Cells Research, Development and Therapy, which is available online at http://ow.ly/ZFzM300Yt1m.
KOOL: 4.00 (-0.03)
Cesca Therapeutics Provides Update on FDA Review of Investigational Device Exemption Supplement for SurgWerks(TM) CLI Pivotal Trial
GlobeNewswire - Mon Aug 01, 5:00AM CDT
FDA Approves Commencement of Phase III Pivotal Trial as Amended
KOOL: 4.00 (-0.03)
Cesca Therapeutics Appoints Mark Bagnall to Its Board of Directors
GlobeNewswire - Mon Jun 20, 5:05AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Mr. Mark Bagnall has been appointed to the Company's Board of Directors, effective July 1, 2016.
KOOL: 4.00 (-0.03)
Cesca Therapeutics to Exhibit at 14th International Cord Blood Symposium
GlobeNewswire - Wed Jun 08, 5:05AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company will be exhibiting at the 14 International Cord Blood Symposium (ICBS), being held June 9-11 at the Hyatt Regency Hotel in San Francisco, California. As a leader in concentrating and cryopreserving stem cells from cord blood, Cesca is proud to sponsor the event.
KOOL: 4.00 (-0.03)
Cesca Therapeutics to Present at the LD Micro Invitational Conference
GlobeNewswire - Mon Jun 06, 5:05AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that Mr. Michael Bruch, the Company's Chief Financial Officer and Dalip Sethi, Ph.D., Clinical Research Director, will discuss recent corporate developments and initiatives at the LD Micro Invitational, being held June 7 - 9, 2016 at the Luxe Sunset Hotel in Los Angeles.
KOOL: 4.00 (-0.03)
Cesca Therapeutics Submits Investigational Device Exemption Supplement for SurgWerks(TM) CLI Pivotal Trial
GlobeNewswire - Wed Jun 01, 10:15AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company has submitted an Investigational Device Exemption (IDE) Supplement to the U.S. Food and Drug Administration (FDA) for its previously approved pivotal trial for the treatment of patients with critical limb ischemia (CLI), using the Company's SurgWerks system. The Company expects the FDA to submit its response to the IDE supplement within 30 days of submission.
KOOL: 4.00 (-0.03)
Cesca Therapeutics to Exhibit at the 2016 International Society for Cellular Therapy Annual Meeting
GlobeNewswire - Tue May 24, 5:00AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company will be exhibiting at the 2016 International Society for Cellular Therapy (ISCT) Annual Meeting in Booth B06 on May 25-28, 2016 at the Suntec Convention and Exhibition Center in Suntec City, Singapore.
KOOL: 4.00 (-0.03)
Cesca Therapeutics to Review Recent Corporate Milestones at the Marcum MicroCap Conference
GlobeNewswire - Fri May 20, 5:00AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that the Company's management team including, Mr. Robin Stracey, Chief Executive Officer, Mr. Michael Bruch, Chief Financial Officer and Dalip Sethi, Ph.D., Clinical Research Director, will discuss recent corporate developments and initiatives at the Marcum MicroCap Conference, which is being held June 1 - 2, 2016 at the Grand Hyatt Hotel in New York City.
KOOL: 4.00 (-0.03)
4 Stocks to Watch on Thursday May 19
ACCESSWIRE - Thu May 19, 1:02PM CDT
CORAL GABLES, FL / ACCESSWIRE / May 19, 2016 / TechStockInsider.com issues the following report: Today is an historic day in the market. It marks the anniversary of The Dow Jones Industrial Average having a record close of 18,312.39. But despite this very positive high in market history, investors have been hit with a rocky trading session on Thursday morning. This has left many, searching for stocks that have found an uptrend and we have been able to identify four stocks that investors are buying up on May 19.
KOOL: 4.00 (-0.03), PRGN: 0.73 (-0.03), GLBS: 0.64 (-0.01)
Cesca Therapeutics Announces Publication of a Case Report on Use of Its Technology for Treatment of Acute Myocardial Infarction
GlobeNewswire - Thu May 19, 5:00AM CDT
Data highlights promising results obtained from the AMIRST pilot study.
KOOL: 4.00 (-0.03)
Cesca Therapeutics Reports Third Quarter Fiscal 2016 Results and Provides Business Update
GlobeNewswire - Thu May 12, 3:37PM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today reported financial results for the third quarter of fiscal 2016 and provided an update to investors that included the status of clinical initiatives, with a particular emphasis on the Company's critical limb ischemia (CLI) program. The Company expects to submit an Investigational Device Exemption (IDE) supplement to the FDA at the end of the month detailing a range of changes to the pivotal CLI trial design and amendments to its CLI study protocol. The supplement will touch on, among other things, study end-points, the statistical analysis plan, the required patient enrollment totals for both the treatment arm and the control arm, patient inclusion/exclusion criteria and protocol changes designed to enhance patient enrollment.
KOOL: 4.00 (-0.03)
Cesca Reports Data From Six CLI Compassionate Use Patients Treated With SurgWerks(TM) Procedures at Fortis Escorts Heart Institute in New Delhi
GlobeNewswire - Wed May 11, 5:00AM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced the results of six late-stage critical limb ischemia (CLI) patients treated with its SurgWerks(TM)-CLI system on a compassionate use basis. In a six-month follow-up of the patients, they reported favorable outcomes in lifestyle and pain reduction. The procedures were conducted by Dr. Suhail Bukhari of the Fortis Escorts Heart Institute and Research Center in New Delhi, India.
KOOL: 4.00 (-0.03)
Cesca Therapeutics to Report Third Quarter Fiscal 2016 Results on May 12, 2016
GlobeNewswire - Mon May 09, 5:00PM CDT
Cesca Therapeutics Inc. (NASDAQ:KOOL), an autologous cell-based regenerative medicine company, today announced that it will report financial results for the fiscal third quarter ended March 31, 2016 and provide a status update to investors on Thursday, May 12, 2016.
KOOL: 4.00 (-0.03)
